KRIBIOLISA™ Liraglutide (Victoza) ELISA

0 ng/ml - 2560 ng/ml

Colorimetric, 450nm

Enzyme Immunoassay for the Quantitative Estimation of Liraglutide in human serum and plasma. Liraglutide (NN2211) is a derivative of a human incretin (metabolic hormone), glucagon-like peptide-1 (GLP-1) that is used as a long-acting glucagon-like peptide-1 receptor agonist, binding to the same receptors as does the endogenous metabolic hormone GLP-1 that stimulates insulin secretion. Marketed under the brand name Victoza, it is an injectable drug developed by Novo Nordisk for the treatment of type 2 diabetes. In 2015, Novo Nordisk began marketing a separate strength in the U.S. and E.U. under the brand name Saxenda as a treatment for adults who are obese or overweight with at least one weight-related comorbid condition. About the kit: - Uses anti-idiotypic antibodies sourced from our vendor partner in the US, which ensures higher specificity, and low cross reactivity. - Recovery rates are between 85 - 115% - Ready to use with a standard protocol with break-apart pre-coated wells - Validated as per US FDA guidelines for Bioassays - Optimized for matrix effects to ensure higher sensitivity. - Shelf life: 1 year The method employs a sandwich immunoassay for the determination of Liraglutide. The anti-Liraglutide Antibodies are coated on microtiter plate. Liraglutide standard and Liraglutide present in the samples will bind to coating antibody. Anti-GLP-1 antibody conjugated to HRP is then added which produces a soluble colored product after addition of TMB substrate. The enzyme reaction is stopped by dispensing of stop solution into the wells. The optical density (OD) of the solution at 450 nm is directly proportional to the amount of bound Liraglutide present in the standards or samples.

Human serum and plasma

40 ng/ml